GlassScriptPhysician profile
Molly Boring
NPI 1417981523
$7,767.24
in general payments reported to CMS, 2019-2025
27 companies · $2,459 in 2025
The $2,459 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $666 · 2022: $1,348 · 2023: $1,339 · 2024: $1,955 · 2025: $2,459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,078 · Education: $675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,077.89 |
| Education | $675.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,382.99 | 2021-2025 | |
| Janssen Biotech, INC. | $1,354.42 | 2021-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $777.60 | 2021-2025 | Ilumya |
| Regeneron Healthcare Solutions, INC. | $629.89 | 2021-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $558.61 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $498.62 | 2021-2025 | |
| Ucb, INC. | $436.66 | 2021-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $350.26 | 2021-2025 | |
| Pfizer INC. | $313.47 | 2021-2025 | |
| Galderma Laboratories, L.P. | $272.14 | 2021-2025 | Nemluvio, Aklief |
| Amgen INC. | $211.49 | 2021-2025 | Otezla, Otezla |
| Incyte Corporation | $206.80 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $124.18 | 2024-2025 | Anzupgo, Adbry |
| Ani Pharmaceuticals, INC. | $110.93 | 2024-2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $110.00 | 2021-2025 | Ebglyss |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.99 | 2022-2025 | Spevigo |
| Vyne Pharmaceuticals INC. | $53.12 | 2021 | |
| Biofrontera INC. | $45.91 | 2023-2025 | Ameluz, Rhodoled Xl, Bf-Rhodoled |
| Mayne Pharma Commercial LLC | $42.08 | 2025 | |
| Verrica Pharmaceuticals INC. | $40.98 | 2024 | Ycanth |
| Dermavant Sciences, INC. | $39.61 | 2024 | Vtama |
| Allergan, INC. | $38.61 | 2022 | |
| Botanix Sb INC | $31.88 | 2025 | Sofdra |
| Organon LLC | $16.71 | 2023 | Hadlima |
| Almirall LLC | $14.98 | 2025 | Klisyri |
| Dermira, INC. | $14.45 | 2021 | |
| Arcutis Biotherapeutics, INC. | $13.86 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Boring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.